Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511784
2.
Immunology across two islands: understanding the research landscape of Aotearoa (New Zealand).
Immunol Cell Biol
; 102(4): 235-239, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921552
3.
Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey.
Eur J Haematol
; 112(4): 621-626, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123137
4.
Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study.
Crit Care
; 28(1): 148, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711155
5.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088119
6.
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Intern Med J
; 54(2): 328-336, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146232
7.
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.
Cancer Immunol Immunother
; 72(7): 2267-2282, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36881133
8.
Immunity without innate lymphoid cells.
Nat Immunol
; 17(11): 1237-1238, 2016 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27760103
9.
Central venous access device practice across haematology and oncology centres in Australia and New Zealand: a cross-sectional survey.
Intern Med J
; 53(3): 426-430, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920141
10.
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
Intern Med J
; 53(1): 119-125, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36371767
11.
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Intern Med J
; 53(9): 1678-1691, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743239
12.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
13.
Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021.
Intern Med J
; 51 Suppl 7: 220-233, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34937138
14.
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
Intern Med J
; 51(5): 763-768, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047035
15.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1188-1200, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888452
16.
Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.
Br J Haematol
; 189(2): 279-290, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31960409
17.
Chimeric antigen receptor T-cell therapies: Optimising the dose.
Br J Clin Pharmacol
; 86(9): 1678-1689, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32175617
18.
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Med J Aust
; 212(10): 481-489, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32401360
19.
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
Intern Med J
; 50(6): 667-679, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415723
20.
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist.
Org Biomol Chem
; 17(5): 1225-1237, 2019 01 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30656346